Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

Zhang, Hui-Qiang; Zhou, Jin-Mei; Zhang, Shao-Hua; Bian, Li; Xiao, Jin-Yi; Hao, Xiao-Peng; Jiang, Ze-Fei; Wang, Tao

Zhang, Hui-Qiang; Zhou, Jin-Mei; Zhang, Shao-Hua; Bian, Li; Xiao, Jin-Yi; Hao, Xiao-Peng; Jiang, Ze-Fei; Wang, Tao.

Afiliação

Zhang HQ; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Zhou JM; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Zhang SH; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Bian L; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiao JY; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Hao XP; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Jiang ZF; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Wang T; Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

Ann Transl Med ; 9(19): 1493, 2021 Oct.

Article em En | MEDLINE | ID: mdl-34805355

Palavras-chave

Everolimus; endocrine therapy; hormone receptor-positive; metastatic breast cancer; real world

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Ann Transl Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google